Abalos Therapeutics Completes Series A Extension Bringing To

Additional EUR 32.5 million will support clinical readiness and accelerate lead immuno-virotherapy candidates toward clinical proof-of-concept Abalos Therapeutics announced today an extension

Related Keywords

Germany , Ruhr , Nordrhein Westfalen , United States , Israel , Berlin , America , German , Kostenloser Wertpapierhandel , Marcus Kostka , Desmond James , Danone , Twitter , Ministry Of Economics , Trophic Communications , Boehringer Ingelheim Venture Fund , Economic Development , Novartis , Droege Group , Fund Investors , European Union , Boehringer Ingelheim Venture Fund Gmb , Health For Life Capital , Seventure Partners , Ventura Biomed Investors , Annegret De Baey , Venture Partner , Isabelle De Cremoux , Managing Partner , Fast Evolution Platform , Abalo Supervisory , North America , Qlife Capital , Biomed Investors , Bio Ventures , Boehringer Ingelheim Venture Fund Gmbh , North Rhine Westphalia , Federal Government , North Rhine Westphalian , Federal Ministry , Kfw Capital , May Desmond James , Abalos , Herapeutics , Ompletes , Series , Extension , Ringing , Total , Aised , Billion ,